Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).
The invention relates to a compound which inhibits the importation of chloride into neurons or a compound which improves the outflow of chloride from neurons for use in the treatment of autism.

**BACKGROUND OF THE INVENTION:**

Infantile Autistic Syndrome Disorders (ASD) include a wide range of abnormalities including a genuine incapacity to organise affective relations, behavioural anomalies in reciprocal social interactions, verbal and non verbal communication, limited interest in the surrounding environment associated with stereotyped movements and repetitive plays (Kanner, 1943; Levy and Hyman, 1993; Levy and Hyman, 2005; Adrien et al., 2001; Blanc et al., 2005; Bourreau et al., 2009). Research to date indicates that a genetic predisposition may play a role in the disease but one or more environmental factors must be in place for symptoms to occur including environmental contaminants and possibly maternal exposures during gestation (Persico and Bourgeron, 2006; Bourgeron, 2009; Patterson, 2002). It is suggested that genetic and environmental hazards will alter developmental programs leading to cortical and/or sub-cortical malformations and the formation of misplaced/misconnected neuronal ensembles. The first symptoms occur before 3 years of age with most likely an earlier origin. Some studies have suggested the use of some compounds for the treatment of autism. In particular Bradstreet et al. (Medical hypotheses 2006 68(5):979-987) discloses the use of Spironolactone, a potassium-sparing diuretic.

Bumetanide (Bum) (Cohen, 1981; Feit, 1981) is a classical diuretic that selectively antagonises the co-transporter NKCC1 - thereby reducing \((\text{Cl}^-)_I\) (Delpire et al., 1999; Delpire and Mount, 2002). Bum has been extensively utilised in adults since 1975 and in children since 1986 and its pharmacokinetic in adults and children and its side effects are well known (Lopez-Samblas et al., 1997; Sullivan et al., 1996; Witte et al., 1986; Marshall et al., 1998). Bum is used in acute (oedema following head trauma) and long term conditions including broncho-pulmonary dysplasia, nephritic syndromes or heart congestions (O'Donnell et al., 2004; Mackie et al., 1986; Sullivan et al., 1996) and has been recently reported to reduce seizure severity in a case report (Kahle et al., 2009). The use of Bum is safe provided that it is accompanied with continuous clinical and biological surveillance notably in children.

The inventors have now investigated in 5 autistic infants the effects of bum with ongoing clinical and biological surveillance. They were selected with no a priori from a large group of Autism Spectrum Disorder (ASD) children placed in institutions or at home to provide a variety of cases. The diuretic was administered (1mg/24h, 0.5mg twice a day) and the treatment continued for 3 months, a minimal duration considered to be sufficient for an evaluation of the effects on infantile autistic syndrome (IAS). We report a significant improvement of the IAS manifestations in the 5 children. These observations call for wide range screening of the use of Bum in IAS and more generally in autism.

**SUMMARY OF THE INVENTION:**

The inventors have made the hypothesis that an antagonist of the NKCC co-transporter which inhibits the importation of chloride into neurons and thereby reduces intracellular concentrations may be useful for the treatment of autism.

Thus the invention relates to a compound which inhibits the importation of chloride into neurons and a compound which improves the outflow of chloride from neurons for use in the treatment of autism.
In another aspect, the invention relates to a pharmaceutical composition for use in the treatment of autism comprising a compound according to the invention and a pharmaceutically acceptable carrier.

One object of the present invention is a compound which decreases the intracellular concentration of chloride within neurons for use in the treatment of autism wherein said compound inhibits the Na-K-Cl (NKCC) co-transporter.

In one embodiment of the invention, said compound is an inhibitor of NKCC1.

In another embodiment of the invention, said compound is a diuretic.

In another embodiment of the invention, said compound is bumetanide or an analog thereof selected from: bumetanide aldehyde, bumetanide dibenzylamide, bumetanide diethylamide, bumetanide morpholinioethyl ester, bumetanide 3-(dimethylaminopropyl) ester, bumetanide N,N-diethylglycolamide ester, bumetanide dimethylglycolamide ester, bumetanide pivaxetil ester, bumetanide methoxy(polyethyleneoxy)n-1-ethyl ester, bumetanide benzyltrimethyl-ammonium salt, and bumetanide cetyltrimethylammonium salt.

Another object of the present invention is a pharmaceutical composition for use in the treatment of autism comprising said compound and a pharmaceutically acceptable carrier.

DETAILED DESCRIPTION OF THE INVENTION:

Definitions

Throughout the specification, several terms are employed and are defined in the following paragraphs.

As used herein, the term "autism" denotes a family of disorders of neural development that is characterized by impaired social interaction and communication, restricted and repetitive behaviour accompanied with other deficits. These signs all begin before a child is three years old. Autism affects information processing in the brain by altering how nerve cells and their synapses connect and organize; how this occurs is not well understood. The two other autism spectrum disorders (ASD) are Asperger syndrome, which lacks delays in cognitive development and language, atypical autism, diagnosed when full criteria for the other two disorders are not met, and PDD-NOS when pervasive developmental disorder are not specified.

As used herein, NKCC for "Na-K-Cl co-transporter" denotes a protein that assists in the active transport of sodium, potassium, and chloride into and out of cells. There are several varieties, or isoforms, of this membrane transport protein, notably NKCC1 and NKCC2. NKCC1 is widely distributed throughout the body but also in the brain and in particular in the developing animal and human brain. It acts to augment intracellular chloride in neurons and thereby to render GABA more excitatory. Extensive investigations indicate that blocking NKCC1 reduce intracellular chloride thereby augmenting the inhibitory actions of GABA. In vivo and in vitro studies have now indicated that genetic and/or pharmacological blockade of NKCC1 reduces early network activity.

As used herein, the term KCC for "potassium chloride co-transporter" denotes a co-transporter of chloride. There are several varieties, or isoforms, notably KCC2. KCC2 is found in many organs notably in the brain acts to remove intracellular chloride and thereby to augment the inhibitory actions of GABA. Blockers of KCC2 transform GABA to excitatory and facilitate the generation of seizures and genetic invalidation of KCC2 is lethal in mice. KCC2 is also expressed relatively late in development paralleling the shift of the actions of GABA from excitatory to inhibitory. Also, a wide range of insults and seizures remove functional KCC2 thereby leading to persistent excitatory actions of GABA and further seizures.

As used herein, the term "diuretic" denotes any drug that elevates the rate of urination and thus provides a means of forced diuresis. There are several categories of diuretics. All diuretics increase the excretion of water from bodies, although each class does so in a distinct way.

As used herein, the term "loop diuretics" denotes diuretics that act on the ascending loop of Henle in the kidney.

As used herein, the term "treating" or "treatment," denotes reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or reversing, alleviating, inhibiting the progress of, or preventing one or more symptoms of the disorder or condition to which such term applies.

Antagonist and uses thereof

A first object of the invention relates to a compound which inhibits the importation of chloride into neurons or a compound which improves the outflow of chloride from neurons for use in the treatment of autism.

In a preferred embodiment, the compound according to the invention inhibits the NKCC co-transporter or activates the KCC co-transporter.

In another preferred embodiment, the compound according to the invention is an antagonist of NKCC co-transporter or an agonist of KCC co-transporter.

In one embodiment, said NKCC antagonist or KCC agonist may be a low molecular weight antagonist, e.g. a small organic molecule (natural or not).
The term "small organic molecule" refers to a molecule (natural or not) of a size comparable to those organic molecules generally used in pharmaceuticals. The term excludes biological macromolecules (e.g., proteins, nucleic acids, etc.). Preferred small organic molecules have a size range up to about 5000 Da, more preferably up to 2000 Da, and most preferably up to about 1000 Da.

In another embodiment, NKCC antagonist or KCC agonist of the invention may consist in an antibody which inhibits NKCC or activates KCC or an antibody fragment which inhibits NKCC or activates KCC.

Antibodies directed against NKCC or KCC can be raised according to known methods by administering the appropriate antigen or epitope to a host animal selected, e.g., from pigs, cows, horses, rabbits, goats, sheep, and mice, among others. Various adjuvants known in the art can be used to enhance antibody production. Although antibodies useful in practicing the invention can be polyclonal, monoclonal antibodies are preferred. Monoclonal antibodies against NKCC or KCC can be prepared and isolated using any technique that provides for the production of antibody molecules by continuous cell lines in culture. Techniques for production and isolation include but are not limited to the hybridoma technique originally described by Kohler and Milstein (1975); the human B-cell hybridoma technique (Cote et al., 1983); and the EBV-hybridoma technique (Cole et al. 1985). Alternatively, techniques described for the production of single chain antibodies (see, e.g., U.S. Pat. No. 4,946,778) can be adapted to produce anti-NKCC or anti-KCC single chain antibodies. NKCC antagonists or KCC agonists useful in practicing the present invention also include anti-NKCC antibody fragments or anti-KCC antibody fragment including but not limited to F(ab')2 fragments, which can be generated by pepsin digestion of an intact antibody molecule, and Fab fragments, which can be generated by reducing the disulfide bridges of the F(ab')2 fragments. Alternatively, Fab and/or scFv expression libraries can be constructed to allow rapid identification of fragments having the desired specificity to NKCC or KCC.

Humanized anti-NKCC antibodies or anti-KCC antibodies and antibody fragments therefrom can also be prepared according to known techniques. "Humanized antibodies" are forms of non-human (e.g., rodent) chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region (CDRs) of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity and capacity. In some instances, framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FRs are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. Methods for making humanized antibodies are described, for example, by Winter (U.S. Pat. No. 5,225,539) and Boss (Celltech, U.S. Pat. No. 4,816,397).

In still another embodiment, NKCC antagonists or KCC agonists may be selected from aptamers. Aptamers are a class of molecule that represents an alternative to antibodies in term of molecular recognition. Aptamers are oligonucleotide or oligopeptide sequences with the capacity to recognize virtually any class of target molecules with high affinity and specificity. Such ligands may be isolated through Systematic Evolution of Ligands by EXponential enrichment (SELEX) of a random sequence library, as described in Tuerk C. and Gold L., 1990. The random sequence library is obtainable by combinatorial chemical synthesis of DNA. In this library, each member is a linear oligomer, eventually chemically modified, of a unique sequence. Possible modifications, uses and advantages of this class of molecules have been reviewed in Jayasena S.D., 1999. Protein aptamers consist of a conformationally constrained antibody variable region displayed by a platform protein, such as, for example, E. coli Thioredoxin A that are selected from combinatorial libraries by two hybrid methods (Colas et al., 1996).

Small inhibitory RNAs (siRNAs) can also function as inhibitors of NKCC co-transporter gene expression for use in the present invention. NKCC co-transporter gene expression can be reduced by contacting a subject or cell with a small double stranded RNA (dsRNA), or a vector or construct causing the production of a small double stranded RNA, such that NKCC co-transporter gene expression is specifically inhibited (i.e. RNA interference or RNAi). Methods for selecting an appropriate dsRNA or dsRNA-encoding vector are well known in the art for genes whose sequence is known (e.g. see Tuschi, T. et al. (1999); Elbashir, S. M. et al. (2001); Hannon, GJ. (2002); MacManus, MT. et al. (2002); Brummelkamp, TR. et al. (2002); U.S. Pat. Nos. 6,573,099 and 6,506,559; and International Patent Publication Nos. WO 01/36646, WO 99/32619, and WO 01/68836).

Ribozymes can also function as inhibitors of NKCC co-transporter gene expression for use in the present invention. Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. The mechanism of ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Engineered hairpin or hammerhead motif ribozyme molecules that specifically and efficiently catalyze endonucleolytic cleavage of NKCC co-transporter mRNA sequences are thereby useful within the scope of the present invention. Specific ribozyme cleavage sites within any potential RNA target are initially identified.
by scanning the target molecule for ribozyme cleavage sites, which typically include the following sequences, GUA, GUU, and GUC. Once identified, short RNA sequences of between about 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site can be evaluated for predicted structural features, such as secondary structure, that can render the oligonucleotide sequence unsuitable. The suitability of candidate targets can also be evaluated by testing their accessibility to hybridization with complementary oligonucleotides, using, e.g., ribonuclease protection assays.

[0033] Both antisense oligonucleotides and ribozymes useful as inhibitors of NKCC co-transporter gene expression can be prepared by known methods. These include techniques for chemical synthesis such as, e.g., by solid phase phosphoramidite chemical synthesis. Alternatively, anti-sense RNA molecules can be generated by in vitro or in vivo transcription of DNA sequences encoding the RNA molecule. Such DNA sequences can be incorporated into a wide variety of vectors that incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters. Various modifications to the oligonucleotides of the invention can be introduced as a means of increasing intracellular stability and half-life. Possible modifications include but are not limited to the addition of flanking sequences of ribonucleotides or deoxyribonucleotides to the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2'-O-methyl rather than phosphodiesterase linkages within the oligonucleotide backbone.

[0034] Antisense oligonucleotides siRNAs and ribozymes of the invention may be delivered in vivo alone or in association with a vector. In its broadest sense, a “vector” is any vehicle capable of facilitating the transfer of the antisense oligonucleotide siRNA or ribozyme nucleic acid to the cells and preferably cells expressing NKCC co-transporter. Preferably, the vector transports the nucleic acid to cells with reduced degradation relative to the extent of degradation that would result in the absence of the vector. In general, the vectors useful in the invention include, but are not limited to, plasmids, phagemids, viruses, other vehicles derived from viral or bacterial sources that have been manipulated by the insertion or incorporation of the antisense oligonucleotide siRNA or ribozyme nucleic acid sequences. Viral vectors are a preferred type of vector and include, but are not limited to nucleic acid sequences from the following viruses: retrovirus, such as moloney murine leukemia virus, harvey murine sarcoma virus, murine mammary tumor virus, and rous sarcoma virus; adenovirus, adeno-associated virus; SV40-type viruses; polyoma viruses; Epstein-Barr viruses; papilloma viruses; herpes virus; vaccinia virus; polio virus; and RNA virus such as a retrovirus. One can readily employ other vectors not named but known to the art.

[0035] In a preferred embodiment, the compound which inhibits the NKCC co-transporter is a diuretic.

[0036] In another preferred embodiment, the diuretic is a loop diuretic.

[0037] In a preferred embodiment, the compound according to the invention is a NKCC1 antagonist.

[0038] In another preferred embodiment, the compound according to the invention is bumetanide.

[0039] In a preferred embodiment, the compound according to the invention is selected from furosemide, ethacrynic acid, torsemide, azosemide, muzolimine, piretanide, triamidine and the like; thiazide and thiazide-like diuretics, such as bendroflumethiazide, benzbithiazide, chlorothiazide, hydrochlorothiazide, hydro-flumethiazide, methylclothiazide, polythiazide, trichlormethiazide, chlorthald lone, indapamide, metolazone and quinethazone; and analogs and functional derivatives of such compounds.

[0040] In a preferred embodiment, an analog according to the invention may have a formula as described in the patent application WO2006110187.

[0041] In a preferred embodiment, the analog may be bumetanide aldehyde, bumetanide dibenzyldiamine, bumetanide diethylamide, bumetanide morpholinooethyl ester, bumetanide 3-(dimethyaminopropyl) ester, bumetanide N,N-diethylglycolamide ester, bumetanide dimethylglycolamide ester, bumetanide pivaxetil ester, bumetanide methoxy(polyethyleneoxy)_{n-1},ethyl ester, bumetanide benzyltrimethylammonium salt, and bumetanide cetyltrimethylammonium salt.

[0042] In another preferred embodiment, the analog may be furosemide aldehyde, furosemide ethyl ester, furosemide cyanomethyl ester, furosemide benzyl ester, furosemide morpholinooethyl ester, furosemide 3-(dimethyaminopropyl) ester, furosemide N,N-diethylglycolamide ester, furosemide dibenzyldiamine, furosemide benzyltrimethylammonium salt, furosemide cetyltrimethylammonium salt, furosemide N,N-dimethylglycolamide ester, furosemide methoxy(polyethyleneoxy)_{n-1},ethyl ester, furosemide pivaxetil ester and furosemide propaxetil ester.

[0043] In another preferred embodiment, the analog may be piretanide aldehyde, piretanide methyl ester, piretanide cyanomethyl ester, piretanide benzyl ester, piretanide morpholinooethyl ester, piretanide 3-(dimethyaminopropyl) ester, piretanide N,N-diethylglycolamide ester, piretanide diethylamide, piretanide dibenzyldiamine, piretanide benzyltrimethylammonium salt, piretanide cetyltrimethylammonium salt, piretanide N,N-dimethylglycolamide ester, piretanide methoxy(polyethyleneoxy)_{n-1},ethyl ester, piretanide pivaxetil ester and/or piretanide propaxetil ester.

[0044] In another preferred embodiment, the analog may be tetrazolyl-substituted azosemides (such as methoxymethyl tetrazolyl-substituted azosemides, methylthiomethyl tetrazolyl-substituted azosemides and N-mPEG350-tetrazolyl-substituted azosemides), azosemide benzyltrimethylammonium salt and/or azosemide cetyltrimethylammonium salt.

[0045] In another preferred embodiment, the analog may be pyridine-substituted torsemide quaternary ammonium salts or the corresponding inner salts (zwitterions). Examples include, but are not limited to, methoxymethyl pyridinium torsemide salts, methylthiomethyl pyridinium torsemide salts and N-mPEG350-pyridinium torsemide salts.
In a preferred embodiment, the compound according to the invention is a KCC2 agonist.

In a preferred embodiment, the compound according to the invention is a compound which inhibits the level of the NKCC protein on the cell surface or improves the level of the KCC protein on the cell surface.

In another preferred embodiment, the cell is a neuron.

Another object of the invention relates to a method for treating autism comprising administering to a subject in need thereof with a compound which inhibits the importation of chloride into neurons or a compound which improve the outflow of chloride from neurons.

In one aspect, the invention relates to a method for treating autism comprising administering to a subject in need thereof a NKCC antagonist as above described.

Compounds of the invention may be administered in the form of a pharmaceutical composition, as defined below.

Preferably, said compound which inhibits the importation of chloride into neurons or which improve the outflow of chloride from neurons, preferably said antagonist of NKCC or said agonist of KCC, is administered in a therapeutically effective amount.

By a “therapeutically effective amount” is meant a sufficient amount of compound to treat and/or to prevent diseases as described previously.

It will be understood that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed, the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific polypeptide employed; and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of the compound at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. However, the daily dosage of the products may be varied over a wide range from 0.01 to 1,000 mg per adult per day. Preferably, the compositions contain 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 250 and 500 mg of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. A medicament typically contains from about 0.01 mg to about 500 mg of the active ingredient, preferably from 1 mg to about 100 mg of the active ingredient. An effective amount of the drug is ordinarily supplied at a dosage level from 0.0002 mg/kg to about 20 mg/kg of body weight per day, especially from about 0.001 mg/kg to 7 mg/kg of body weight per day.

Compounds according to the invention may be used for the preparation of a pharmaceutical composition for use in the treatment of autism.

Hence, the present invention also provides a pharmaceutical composition comprising an effective dose of a compound which inhibits the NKCC co-transporter; preferably a NKCC antagonist or which activates the KCC co-transporter, according to the invention.

Any therapeutic agent of the invention may be combined with pharmaceutically acceptable excipients, and optionally sustained-release matrices, such as biodegradable polymers, to form therapeutic compositions.

"Pharmaceutically" or "pharmaceutically acceptable" refers to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to a mammal, especially a human, as appropriate. A pharmaceutically acceptable carrier or excipient refers to a non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.

The form of the pharmaceutical compositions, the route of administration, the dosage and the regimen naturally depend upon the condition to be treated, the severity of the illness, the age, weight, and sex of the patient, etc.

The pharmaceutical compositions of the invention can be formulated for a topical, oral, intranasal, parenteral, intraocular, intravenous, intramuscular or subcutaneous administration and the like.

Preferably, the pharmaceutical compositions contain vehicles which are pharmaceutically acceptable for a formulation capable of being injected. These may be in particular isotonic, sterile, saline solutions (monosodium or disodium phosphate, sodium, potassium, calcium or magnesium chloride and the like or mixtures of such salts), or dry, especially freeze-dried compositions which upon addition, depending on the case, of sterilized water or physiological saline, permit the constitution of injectable solutions.

The doses used for the administration can be adapted as a function of various parameters, and in particular as a function of the mode of administration used, of the relevant pathology, or alternatively of the desired duration of treatment.

In addition, other pharmaceutically acceptable forms include, e.g. tablets or other solids for oral administration; time release capsules; and any other form currently can be used. Pharmaceutical composition according to the invention may also contain other compounds, which may be biologically active or inactive. For example, one or more treatment agents of the present invention may be combined with another agent, in a treatment combination, and administered according to a treatment regimen of the present invention. Such combinations may be administered as separate com-
positions, combined for delivery in a complementary delivery system, or formulated in a combined composition, such as a mixture or a fusion compound. Additionally, the aforementioned treatment combination may include a BBB permeability enhancer and/or a hyperosmotic agent.

Alternatively, compounds of the invention which inhibits the NKCC co-transporter or activates the KCC co-transporter can be further identified by screening methods as hereinafter described.

**Screening methods**

Another object of the invention relates to a method for screening a compound which inhibits the NKCC co-transporter of activates the KCC co-transporter.

In particular, the invention provides a method for screening a NKCC antagonist or a KCC agonist for the treatment of autism.

For example, the screening method may measure the binding of a candidate compound to NKCC or KCC, or to cells or membranes bearing NKCC or KCC or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound. Alternatively, a screening method may involve measuring or, qualitatively or quantitatively, detecting the competition of binding of a candidate compound to the receptor with a labelled competitor (e.g., antagonist).

Furthermore, screening methods may test whether the candidate compound results in a signal generated by an antagonist of NKCC or an agonist of KCC, using detection systems appropriate to cells bearing the receptor.

In a particular embodiment, the screening method of the invention comprises the step consisting of:

a) providing neurons expressing NKCC or KCC on their surface;

b) incubating said cells with a candidate compound;

c) determining whether said candidate compound binds to and inhibits NKCC or binds to and activates KCC; and

d) selecting the candidate compound that binds to and inhibits NKCC or binds to and activates KCC.

In one embodiment, the NKCC co-transporter or the KCC co-transporter used in the screening method may be its orthologs and derivatives as defined in the present invention.

In general, such screening methods involve providing appropriate cells which express NKCC or KCC, its orthologs and derivatives thereof on their surface. In particular, a nucleic acid encoding NKCC or KCC may be employed to transfect cells to thereby express the receptor of the invention. Such a transfection may be accomplished by methods well known in the art.

In a particular embodiment, cells are selected from the group consisting of glial cells, neuronal cells, neurons, transfected cell lines for investigations or renal cells of any species (mouse, human...).

The screening method of the invention may be employed for determining an antagonist or agonist by contacting such cells with compounds to be screened and determining whether such compound inhibits or activates the co-transporter.

The determination of the inhibition of NKCC can be assessed by determining the cell viability. A compound is deemed to decrease cell viability if it is negative in any one the methods described below as examples of cell rescue activity.

According to a one embodiment of the invention, the candidate compound may be selected from a library of compounds previously synthesised, or a library of compounds for which the structure is determined in a database, or from a library of compounds that have been synthesised de novo or natural compounds.

The candidate compound may be selected from the group of (a) proteins or peptides, (b) nucleic acids and (c) organic or chemical compounds (natural or not). Illustratively, libraries of pre-selected candidate nucleic acids may be obtained by performing the SELEX method as described in documents US 5,475,096 and US 5,270,163. Further illustratively, the candidate compound may be selected from the group of antibodies directed against NKCC or KCC.

Such method may be used to screen NKCC antagonists or KCC agonists according to the invention.

The invention will be further illustrated by the following tables and examples. However, these examples and figures should not be interpreted in any way as limiting the scope of the present invention.

| Table 1 |
|---|---|---|---|---|---|---|
| age | sex | diagno | ADI1 | ADI2 | ADI3 | ADI4 |
| 1 | 8 yrs 11 mths | M | F84.00 | 18 (10) | 13 (8) | 5 (3) | 5 (1) |
| 2 | 3 yrs 8 mths | F | F84.00 | 20 (10) | 8 (7) | 4 (3) | 5 (1) |

Summary of patients included in the study. 4 girls and one boy aged between 3 years and 8 months to 11 years and 5 months with classical autistic signs (F84.0 of the ICD 10).
EXAMPLE:

Material & Methods

[0079] The inventors have investigated in 5 autistic infants the effects of bum with ongoing clinical and biological surveillance. They were selected with no a priori from a large group of IAS children placed in institutions or at home to provide a variety of cases. The diuretic was administered (1mg/24h, 0.5mg twice a day) and the treatment continued for 3 months, a minimal duration considered to be sufficient for an evaluation of the effects on IAS. We report a significant

Summary of patients included in the study. 4 girls and one boy aged between 3 years and 8 months to 11 years and 5 months with classical autistic signs (F84.0 of the ICD 10).

<table>
<thead>
<tr>
<th>age</th>
<th>sex</th>
<th>diagno</th>
<th>ADI1</th>
<th>ADI2</th>
<th>ADI3</th>
<th>ADI4</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>8 yrs 7 mths</td>
<td>M</td>
<td>F84.00</td>
<td>21 (10)</td>
<td>8 (7)</td>
<td>5 (3)</td>
</tr>
<tr>
<td>4</td>
<td>11 yrs 5 mths</td>
<td>M</td>
<td>F84.00</td>
<td>24 (10)</td>
<td>14 (7)</td>
<td>4 (3)</td>
</tr>
<tr>
<td>5</td>
<td>10 yrs 1 mth</td>
<td>M</td>
<td>F84.00</td>
<td>17 (10)</td>
<td>20 (8)</td>
<td>4 (3)</td>
</tr>
</tbody>
</table>

Table 2

Summary scores of the effects of bumetanide in the five patients (C = controls before the treatment, Bum = 3 months after bumetanide).

<table>
<thead>
<tr>
<th></th>
<th>C</th>
<th>Bum</th>
<th>C</th>
<th>Bum</th>
<th>C</th>
<th>Bum</th>
<th>C</th>
<th>Bum</th>
</tr>
</thead>
<tbody>
<tr>
<td>CARS total</td>
<td>38.5</td>
<td>28.0</td>
<td>40.5</td>
<td>36.0</td>
<td>38.0</td>
<td>30.0</td>
<td>53.5</td>
<td>49.0</td>
</tr>
<tr>
<td>CARS nb item sup to 3</td>
<td>7.0</td>
<td>1.0</td>
<td>7.0</td>
<td>4.0</td>
<td>9.0</td>
<td>4.0</td>
<td>14.0</td>
<td>11.0</td>
</tr>
<tr>
<td>ABC total</td>
<td>84.0</td>
<td>57.0</td>
<td>79.0</td>
<td>49.0</td>
<td>89.0</td>
<td>62.0</td>
<td>93.0</td>
<td>79.0</td>
</tr>
<tr>
<td>ABC1</td>
<td>20.0</td>
<td>17.0</td>
<td>9.0</td>
<td>3.0</td>
<td>3.0</td>
<td>12.0</td>
<td>26.0</td>
<td>19.0</td>
</tr>
<tr>
<td>ABC2</td>
<td>9.0</td>
<td>1.0</td>
<td>19.0</td>
<td>11.0</td>
<td>12.0</td>
<td>5.0</td>
<td>26.0</td>
<td>19.0</td>
</tr>
<tr>
<td>ABC3</td>
<td>12.0</td>
<td>6.0</td>
<td>10.0</td>
<td>6.0</td>
<td>13.0</td>
<td>3.0</td>
<td>15.0</td>
<td>12.0</td>
</tr>
<tr>
<td>ABC4</td>
<td>39.0</td>
<td>28.0</td>
<td>41.0</td>
<td>29.0</td>
<td>32.0</td>
<td>33.0</td>
<td>37.0</td>
<td>33.0</td>
</tr>
<tr>
<td>ABC5</td>
<td>4.0</td>
<td>5.0</td>
<td>0.0</td>
<td>12.0</td>
<td>9.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>CGI1</td>
<td>5.0</td>
<td>5.0</td>
<td>7.0</td>
<td>7.0</td>
<td>5.0</td>
<td>7.0</td>
<td>4.0</td>
<td>4.0</td>
</tr>
<tr>
<td>CGI2</td>
<td>3.0</td>
<td>3.0</td>
<td>3.0</td>
<td>3.0</td>
<td>3.0</td>
<td>3.0</td>
<td>3.0</td>
<td>3.0</td>
</tr>
<tr>
<td>CGI3</td>
<td>3.0</td>
<td>3.0</td>
<td>3.0</td>
<td>3.0</td>
<td>3.0</td>
<td>3.0</td>
<td>3.0</td>
<td>3.0</td>
</tr>
<tr>
<td>RDEG total</td>
<td>49.0</td>
<td>28.0</td>
<td>60.0</td>
<td>48.0</td>
<td>39.0</td>
<td>37.0</td>
<td>75.0</td>
<td>69.0</td>
</tr>
<tr>
<td>RDEG dysregulation</td>
<td>30.0</td>
<td>20.0</td>
<td>37.0</td>
<td>34.0</td>
<td>29.0</td>
<td>31.0</td>
<td>50.0</td>
<td>45.0</td>
</tr>
<tr>
<td>RDEG slowness</td>
<td>12.0</td>
<td>5.0</td>
<td>14.0</td>
<td>8.0</td>
<td>6.0</td>
<td>5.0</td>
<td>15.0</td>
<td>14.0</td>
</tr>
<tr>
<td>RRB total</td>
<td>51.0</td>
<td>32.0</td>
<td>69.0</td>
<td>26.0</td>
<td>63.0</td>
<td>31.0</td>
<td>46.0</td>
<td>40.0</td>
</tr>
<tr>
<td>RRB F1</td>
<td>21.0</td>
<td>15.0</td>
<td>21.0</td>
<td>13.0</td>
<td>12.0</td>
<td>6.0</td>
<td>16.0</td>
<td>14.0</td>
</tr>
<tr>
<td>RRB F2</td>
<td>1.0</td>
<td>1.0</td>
<td>12.0</td>
<td>0.0</td>
<td>20.0</td>
<td>7.0</td>
<td>2.0</td>
<td>2.0</td>
</tr>
<tr>
<td>RRB F3</td>
<td>17.0</td>
<td>6.0</td>
<td>18.0</td>
<td>9.0</td>
<td>19.0</td>
<td>9.0</td>
<td>18.0</td>
<td>16.0</td>
</tr>
<tr>
<td>RRB F4</td>
<td>10.0</td>
<td>8.0</td>
<td>14.0</td>
<td>4.0</td>
<td>9.0</td>
<td>8.0</td>
<td>8.0</td>
<td>6.0</td>
</tr>
</tbody>
</table>
improvement of the IAS manifestations in the 5 children. These observations call for wide range screening of the use of Bum in IAS.

Children were diagnosed by experienced clinical psychiatrist using strict ICD-10 (OMS 1993) criteria for autistic disorder. These children had no history of neurological disease (normal EEG) Genetic tests systematically performed were negative indicating no identifiable mutation (Caryotype and fragile X). The ADI-R (Le Couteur et al., 1989; Lord et al., 1994) was collected for all participants to confirm the diagnoses. A clinical and biological examinations showed that none of the children had a counter indication to bum (including blood ionogram, transaminases, alkaline phosphatases, uremia, creatinemia, creatinine clearance, yGT, glycemia notably). Since hypokalemia can induce wave burst arrhythmia, an ECG was performed to ensure that none of the patients had a lengthening of the QT because they have a higher propensity to generate arrhythmia. A clinical weekly surveillance was performed during the first, second and third month after treatment onset including blood sodium and potassium one week and 2 months after treatment onset. None of the infants had associated neurological disorders and none was under other treatment since at least three months.

To determine the possible therapeutic index efficacy, we relied on 5 classical behavioural determination of IAS severity including:

i) The Childhood Autism Rating Scale (CARS) is a 15-item rating scale that is used as a screening instrument and to assess the changes in symptoms of autism over time. These items comprise a broad range of symptoms of autism and are graded on a scale of 1 to 4, with 1 indicating normal behaviour and 4 denoting severely abnormal and/or inappropriate behaviour. The total score is determined by adding the 15 items. The number of items with a scale equal or superior to 3 is a strong indication of syndrome severity whereas a fall in either the total score after treatment and/or of the number of items equal or above 3, indicates improvement in the severity of autistic features (Rogers et al., 1993). This instrument was developed to aid the diagnostic process but is also sensitive to developmental changes in autistic symptoms (Schopler et al., 1980; Mesibov et al., 1989) and can be used to determine alterations produced by a treatment (Di Lalla and Rogers 1994 also see the French version of B. Rogé 1989). The notation was obtained during a session when the infants were placed in a game and animated discussion with the parents concerning the behaviour of the child during the last week.

ii) The ABC (Aberrant Behaviour Checklist) is a questionnaire filled by the treating doctor during a discussion with the parents (Aman et al., 1985; Rojahn and Helsel 1991). It is widely used in therapeutic trials to evaluate the impact of molecules on behaviour. ABC is a 58-item standardized problem with behaviour checklist that allows item rating on a 4-point scale from 0 (not occurring at all) to 3 (severe). The checklist questions comprise 5 subscales: Irritability (ABC1), Social Withdrawal (ABC2), Stereotypy (ABC3), Hyperactivity (ABC4) and Excessive Speech (ABC5). ABC has been validated on a large scale in the US and is adapted to studies of infantile populations. A French version has been used in the present study (Bouvard et al. 2000).

iii) The Clinical Global Impressions (CGI) is widely used in the majority of clinical trials to examine disease severity. It is scaled from 0 to 7, with 1 being the normal value and it is considered a good estimation of the global situation of the patient. The clinician is asked to give a quotation of the disease as a function of his /her experience with other patients included in the investigation. The second impression provides an estimation of the global improvement of the patient and amelioration when compared to the onset of the trial. There are 7 levels; zero indicating no evolution. The third impression is the most useful as it concerns the therapeutic index and requires a single estimation that indicate both the therapeutic and side effects. This is utilised in research on novel generation psychotic agents with little side effects (Guy 1976).

iv) RDEG the regulation disorder Evaluation grid is a French scale of activity (96) that enables to detect the level of dysregulation, and the slowness of response of the infants (Adrien 1996; Adrien et al. 2001, Blanc et al. 2005). The questionnaire is filled by the parents and concerns the behaviour of the children during the last week.

v) The Repetitive and Restricted Behaviour (RRB) scale (Bourreau et al 2009) is a 35-item standardized checklist, that allows item rating on a 5-point scale from 0 -the behaviour is never expressed by the person- to 4 -the behaviour is severely expressed and characteristic of the person). Factorial analysis produces four clinical meaningful factors, i.e. sensori-motor stereotypes (F1), reaction to change (F2), restricted behaviours (F3) and modulation insufficiency (F4).

Results

A summary of the patients is shown in Table 1. 3 boys used a functional language, whereas the remaining boy and girl did not. The scores of ADI-R are above the threshold confirming the clinical diagnosis. Childs 1, 3, 5 follow a traditional school accompanied by an auxiliary person. During the year, child 1 and child 2 are followed by a psychologist using the ABA approach once a week for child 1 and 3 times a week for child 2). Child 2 has also 2 weekly session of orthophony relying on picture exchange communication system (PECS). Child 3 has an orthopnic treatment weekly and child 5 has no treatment. Child 4 is treated in a medical institution specialised in mentally retarded children. The
test of bum was made during the summer vacation, when behavioural therapy and school were interrupted. 

Table 2 shows the scores of the different scales used and those obtained before and after three months treatment. Before the treatment, 4 children (1, 2, 3, 4) had a CARS score above 36 indicating a severe IAS. Child 5 showed a moderate degree of autism. Results show an improvement of the total scores of CARS, ABC, RDEG and RRB for all children three months after the treatment. CGI1 was not significantly altered but this test concerns the severity of the disease that at this stage does not reveal significant changes. We also observed a small global amelioration of CGI2 for the 5 children. Patients 1, 2 and 5 had an index of 3 in CGI3 indicating a moderate action with no side effects. Patients 3 and 4 had an index of 2 indicating a minimal action with no side effects. The number of items equal or above 3 with CARS was reduced by the treatment in the five children. The sub-score of ABC5, was not altered by the treatment. In the five children, ABC2, ABC3, ABC4, RDEG dysregulation, RDEG slowness, RRB4; RRB F1 were ameliorated to a variable degree. In contrast, the results of ABC1, RRB F2, RRB F3 are heterogeneous.

Starting one week after the treatment and once monthly, a clinical surveillance was made including research of dehydration, orthostatic hypotension, hyper-sensitivity, cramps, asthenia, diarrhea, myalgia, arthralgia, nausea, dizziness. The levels of sodium and potassium remained stable (tests made a week and 2 months after the beginning of the treatment. No adverse effect was found.

Discussion

Present results suggest that bumetanide ameliorates behavioural aspects of IAS suggesting that the diuretic has a global action. To the best of our knowledge, this is the first report raising the possibility of chloride alterations in autism.

The conclusions derived from these observations are hampered by several limitations including the lack of randomized double blind and placebo investigations - due to the limited number of cases. Placebo effects are more prevalent in children than adults (Rheims et al., 2008) this also applies to autism (Sandler 2005). Clearly, wide scale investigations are needed to confirm or infirm the observations. We are aware of these limitations to demonstrate the positive effects of bumetanide and entangle its actions on IAS. Nevertheless, our observations indicate that bumetanide has no side effects with a general tolerance to the diuretic. Also, we were encouraged to present these observations by the dramatic behavioural amelioration suggested by the results and the insistence of the parents that their children are more present and their wish to pursue the treatment speaking in favour of a significant action of bum. In spite of the difficulty in translating this subjective notion, it is interesting to stress that the same term of presence was used by all parents.

It is not possible at present to determine whether bumetanide exerts a preferential action on one aspect of the symptomatology. The lack of effects of bumetanide on ABC5 - inappropriate, excessive speech out of context- is expected because amelioration in 3 months of speech is unlikely to occur. In contrast almost all scores were ameliorated to variable degrees stressing the general action of bumetanide. Alteration of cognitive and emotional behaviour is a basic feature of IAS (Kanner, 1943; Hill and Frith, 2003; Hill, 2004; Bieberich and Morgan, 2004) and the fact that bumetanide enables a better cognitive regulation is perhaps to be correlated with the improved presence reported by the parents. The results of the subscales of ABC suggest an amelioration of states of vigilance and social interactions, stereotypic movements and hyperactivity again in keeping with the notion of cognitive regulation. The pharmaco-dynamic of bumetanide has been investigated in human neonates (Sullivan et al., 1996; Lopez-Samblas et al., 1997) and a recent report suggests that bumetanide reduces seizure severity in an epileptic child (Kahle et al., 2009). A wide range of experimental investigations suggest that bumetanide reduces seizure severity (Kahle and Staley, 2008; Kahle et al., 2008; Nardou et al., 2009). Bumetanide is currently being investigated as a novel treatment for neonatal seizures (EU FP7 Nemo project).

The observations are compatible with the working hypothesis that bumetanide enhances the efficacy of neuronal integrative processes by reducing intracellular chloride and reinforcing the inhibitory actions of GABA. The basic conceptual frame of these investigations is that neurons who fail to respect the developmental program keep immature features-including possibly high (Cl-)I and other electrical and architectural properties (Ben-Ari, 2008). Other observations suggest a link between GABAergic signals and autism (Minshew, 1997; Hussman, 2001; Schmitz et al., 2005). Also, several brain imaging observations indicate a significant loss of GABA/benzodiazepines receptors in autism notably in the hippocampus, cerebellum and various limbic structures (Garreau et al., 1993; Oblak et al., 2009; Guptill et al., 2007; Blatt, 2005).

In conclusion, an emerging series of studies suggest that chloride accumulates during brain maturation in relation to various developmental malformations. Present observations suggest that a conventional diuretic that reduces this accumulation and acts to reinstate the inhibitory actions of GABA may exert beneficial actions in autism calling for more detailed experimental and clinical studies on the links between GABA/(Cl-)I and IAS.
Throughout this application, various references describe the state of the art to which this invention pertains. The disclosures of these references are hereby incorporated by reference into the present disclosure.


DiLalla D.L., Rogers S.J. (1994) Domains of the Childhood Autism Rating Scale: relevance for diagnosis and treat-


The ICD-10 Classification of Mental and Behavioural disorders: Diagnostic criteria for research (1993), World Health Organization.


**Claims**

1. A compound which decreases the intracellular concentration of chloride within neurons for use in the treatment of autism wherein said compound inhibits the Na-K-Cl (NKCC) co-transporter.

2. A compound for use according to the claim 1, wherein said compound is an inhibitor of NKCC1.

3. A compound for use according to claim 1 or 2, wherein the compound is a diuretic.

4. A compound for use according to any one of claims 1 to 3, wherein the compound is bumetanide or an analog thereof selected from: bumetanide, bumetanide aldehyde, bumetanide dibenzylamide, bumetanide diethylamide, bumetanide morpholinoethyl ester, bumetanide 3-(dimethylaminopropyl) ester, bumetanide N,N-diethyglycolamide ester, bumetanide dimethylglycolamide ester, bumetanide pivacetil ester, bumetanide methoxy(polyethyleneoxy)\textsubscript{1-1}-ethyl ester, bumetanide benzytrimethyl-ammonium salt, and bumetanide cetyltrimethylammonium salt.

5. A compound for use according to any one of claims 1 to 4, wherein the compound is bumetanide.

6. A pharmaceutical composition for use in the treatment of autism comprising a compound according to any one of claims 1 to 5 and a pharmaceutically acceptable carrier.

**Patentansprüche**

1. Verbindung, die die intrazelluläre Konzentration von Chlorid in Neuronen verringert, zur Verwendung bei der Behandlung von Autismus, wobei die Verbindung den Na-K-Cl-Cotransporter (NKCC) hemmt.

2. Verbindung zur Verwendung nach Anspruch 1, wobei die Verbindung ein NKCC1-Hemmer ist.

3. Verbindung zur Verwendung nach Anspruch 1 oder 2, wobei die Verbindung ein Diuretikum ist.

4. Verbindung zur Verwendung nach einem der Ansprüche 1 bis 3, wobei die Verbindung Bumetanid oder ein Analogon davon ist, das aus folgenden ausgewählt ist: Bumetanid, Bumetanid-Aldehyd, Bumetanid-Dibenzylamide, Bumetanid-Diethylamide, Bumetanid-Morpholinoethylester, Bumetanid-3-(Dimethylaminopropyl)ester, Bumetanid-N,N-Diethyglycolamidester, Bumetanid-Dimethylglycolamidester, Bumetanid-Pivacetilester, Bumetanid-Methoxy(polyethylene-
oxy)n-1-ethylester, Bumetanid-Benzyltrimethylammoniumsalz und Bumetanid-Cetyltrimethylammoniumsalz.

5. Verbindung zur Verwendung nach einem der Ansprüche 1 bis 4, wobei die Verbindung Bumetanid ist.

6. Pharmazeutische Zusammensetzung zur Verwendung bei der Behandlung von Autismus, die eine Verbindung nach einem der Ansprüche 1 bis 5 und einen pharmazeutisch akzeptablen Trägerstoff umfasst.

Revendications

1. Un composé qui diminue la concentration intracellulaire de chlorure dans les neurones pour son utilisation dans le traitement de l’autisme, dans lequel ladite composition inhibe le co-transporteur Na-K-Cl (NKCC).

2. Composé pour son utilisation selon la revendication 1, dans lequel ledit composé est un inhibiteur de NKCC1.

3. Composé pour son utilisation selon la revendication 1 ou 2, dans lequel ledit composé est un diurétique.

4. Composé pour son utilisation selon l’une quelconque des revendications 1 à 3, dans lequel ledit composé est bumétanide ou un analogue de celui-ci sélectionné parmi : bumétanide, aldéhyde bumétanide, dibenzylamide bumétanide, diéthylamide bumétanide, ester de morpholinoéthyle bumétanide, ester de 3-(diméthylaminopropyl) bumétanide, ester de N,N-diéthylglycolamide bumétanide, ester de diméthylglycolamide bumétanide, ester de pivaxetil bumétanide, ester de méthoxy(polyéthylèneoxy)n-1-éthyl bumétanide, sel de benzyltriméthylammonium bumétanide, et sel de cétyltriméthylammonium bumétanide.

5. Composé pour son utilisation selon l’une quelconque des revendications 1 à 4, dans lequel ledit composé est bumétanide.

6. Une composition pharmaceutique pour son utilisation dans le traitement de l’autisme comprenant un composé selon l’une quelconque des revendications 1 à 5, et un support pharmaceutiquement acceptable.
REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader’s convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 2006089350 A [0004]
- WO 2010085352 A [0004]
- US 4946778 A [0028]
- US 5225539 A [0029]
- US 4816397 A [0029]
- US 6573099 B [0031]
- US 6506559 B [0031]
- WO 0136646 A [0031]
- WO 9932619 A [0031]
- WO 0168836 A [0031]
- WO 2006110187 A [0040]
- US 5475096 A [0076]
- US 5270163 A [0076]

Non-patent literature cited in the description

- BLANC R ; ADRIEN JL ; ROUX S ; BARTHELEMY C. Dysregulation of pretend play and communication development in children with autism. Autism, 2005, vol. 9, 229-245 [0090]
- BOUVARD M. Liste des comportements aberrants-version traduite, Issy les moulineaux. EAP/ECPA, 2000 [0090]


• NARDOU R; BEN-ARI Y; KHALILOV I. Bumetanide, an NKCC1 antagonist, does not prevent formation of epileptogenic focus but blocks epileptic focus seizures in immature rat hippocampus. *J Neurophysiol*, 2009, vol. 101, 2878-2888 [0090]


• RIVERA C; VOIPIO J; PAYNE JA; RUUSUVORI E; LAHTINEN H; LAMSA K; PIRVOLA U; SAARMA M; KAILA K. The K+Cl- co-transporter KCC2 renders GABA hyperpolarizing during neuronal maturation. *Nature*, 1999, vol. 397, 251-255 [0090]


• SULLIVAN JE; WITTE MK; YAMASHITA TS; MYERS CM; BLUMER JL. Pharmacokinetics of bumetanide in critically ill infants. *Clin Pharmacol Ther*, 1996, vol. 57, 405-413 [0090]
